June 6, 2023 12:06 PM EDTUpdated June 7, 11:12 AM
News Briefing

Ital­ian AAV biotech clos­es $65M Se­ries A; GSK's Jem­per­li nabs pri­or­i­ty re­view in en­dome­tri­al can­cer

Amber Tong

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

AA­Vant­garde, a Mi­lan-based AAV biotech, has closed a €61 mil­lion ($65.1 mil­lion) Se­ries A round.

The biotech cur­rent­ly has two AAV plat­forms, one us­ing DNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times